Aprea Therapeutics (APRE) Stock Forecast & Price Target

Aprea Therapeutics is a promising clinical-stage precision medicine oncology company with a strong pipeline of small molecule inhibitors designed to target specific genetic mutations in cancer. The recent update on their WEE1 inhibitor, APR-1051, included a confirmed partial response in a patient with PPP2R1A-mutated uterus serous carcinoma and a reduction in a common endometrial cancer marker. Additionally, the company has a favorable tolerability profile and has recently completed a successful private placement, positioning them for continued success and progress in their clinical trials.

Aprea Therapeutics is facing major challenges with only one confirmed partial response in its ongoing Phase 1 ACESOT-1051 dose escalation trial, which is evaluating the WEE1 kinase inhibitor APR-1051 in patients with advanced solid tumors. The company's pipeline includes other early-stage programs, but a lack of positive clinical results and the need for further studies and updates do not bode well for its financial outlook. The company's current financials are not promising, with a projected total depletion of cash by the end of 2021.